Illumina, Inc. (ILMN)

121,05 -1,82 (-1,48%) Börsenschluss: 04:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 10.590

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jacob Thaysen Ph.D.	CEO & Director	796,63k	N/A	1975
Ms. Carissa L. Rollins	Chief Information Officer	693,52k	N/A	1970
Mr. Charles E. Dadswell Esq.	Senior VP & General Counsel	1,03M	N/A	1959
Dr. Joydeep Goswami M.B.A., Ph.D.	Advisor	843,55k	N/A	1971
Stephanie Campos	President	N/A	N/A	N/A
Mr. Ankur Dhingra	Chief Financial Officer	N/A	N/A	1976
Mr. Kevin Carl Pegels	Chief of Global Operations	N/A	N/A	1968
Mr. Scott Ericksen	VP & Chief Accounting Officer	N/A	N/A	1973
Dr. Steven Barnard Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Ms. Sallilyn Schwartz	Vice President of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Corporate Governance

Illumina, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 7, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.